ChAracterisation of ItaliaN Severe Uncontrolled Asthmatic patieNts Key Features When Receiving Benralizumab

Conditions

Severe Asthma

Brief summary

This is an observational, Italian multi-center, retrospective cohort study with enrollment visit on patients suffering from severe eosinophilic asthma who started benralizumab in the Sampling Program or as per normal clinical practice in Italy.

Detailed description

A retrospective cohort study design involving secondary data collection was chosen to appropriately address the primary objective in a relatively short period of time after enrollment phase initiation: in fact, since the Italian Sampling Program on benralizumab was active since July 2018, clinical data on patients exposed to benralizumab are already available. No treatments will be administered per protocol requirement, but instead according to normal clinical practice; since benralizumab first administration occurs before inclusion in the study (as per chosen study design), the decision to include the patient in the study is clearly separated from the prescription of benralizumab, in accordance with the observational nature of the study. In order to be eligible for the study, for each patient, the index date shall be at least 3 months prior to enrollment.

Luisa Brussino, Maria Aliani, Elena Altieri, Pietro Bracciale, Maria Filomena Caiaffa et al. (22 authors)

Frontiers in Allergy2025-03-201 citations

10.3389/falgy.2025.1501196

Effects of benralizumab in patients with severe eosinophilic asthma (SEA): A plain language summary of the ANANKE study.

Canonica GW, Consani L, Malerba L, Pelaia G, Vultaggio A, ANANKE investigators.

2024-09-171 citations

10.1080/1750743x.2024.2386899

Sustained Effectiveness of Benralizumab in Naïve and Biologics-Experienced Severe Eosinophilic Asthma Patients: Results from the ANANKE Study.

Cameli P, Aliani M, Altieri E, Bracciale P, Brussino L, Caiaffa MF, Canonica GW, Caruso C, Centanni S, D'Amato M, De Michele F, Del Giacco S, Di Marco F, Pelaia G, Rogliani P, Romagnoli M, Schino P, Schroeder JW, Senna G, Vultaggio A, Benci M, Boarino S, Menzella F.

2024-03-272 citations

10.2147/jaa.s438981

Long-term effectiveness of benralizumab in severe eosinophilic asthma patients treated for 96-weeks: data from the ANANKE study.

Vultaggio A, Aliani M, Altieri E, Bracciale P, Brussino L, Caiaffa MF, Cameli P, Canonica GW, Caruso C, Centanni S, D'Amato M, De Michele F, Del Giacco S, Di Marco F, Menzella F, Pelaia G, Rogliani P, Romagnoli M, Schino P, Senna G, Benci M, Boarino S, Schroeder JW.

2023-05-2026 citations

10.1186/s12931-023-02439-w

Clinical Features and Efficacy of Benralizumab in Patients with Blood Eosinophil Count Between 300 and 450 Cells/mm<sup>3</sup>: A Post Hoc Analysis from the ANANKE Study.

Senna G, Aliani M, Altieri E, Bracciale P, Brussino L, Caiaffa MF, Cameli P, Canonica GW, Caruso C, D'Amato M, De Michele F, Del Giacco S, Di Marco F, Menzella F, Pelaia G, Rogliani P, Romagnoli M, Schino P, Schroeder JW, Vultaggio A, Rizzoli S, Zullo A, Boarino S, Palmisano M, Rossi A, Vitiello G, Centanni S.

2022-11-103 citations

10.2147/jaa.s383012

ChAracterization of ItaliaN severe uncontrolled Asthmatic patieNts Key features when receiving Benralizumab in a real-life setting: the observational rEtrospective ANANKE study.

Menzella F, Bargagli E, Aliani M, Bracciale P, Brussino L, Caiaffa MF, Caruso C, Centanni S, D'Amato M, Del Giacco S, De Michele F, Di Marco F, Pastorello EA, Pelaia G, Rogliani P, Romagnoli M, Schino P, Senna G, Vultaggio A, Simoni L, Ori A, Boarino S, Vitiello G, Altieri E, Canonica GW.

2022-02-1931 citations

10.1186/s12931-022-01952-8

Interventions

OTHERNo intervention

Patients currently in treatment with benralizumab as per approved indication and clinical practice

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Healthy volunteers

No

Inclusion criteria

1. Adult patients (age ≥18 years) at the start of benralizumab treatment within the sampling program or per clinical practice (index date). 2. Patients with severe eosinophilic asthma requiring a stable treatment of high doses of inhaled corticosteroids and a long acting β2 agonist ± additional asthma controller (according to clinician's judgment). 3. Patients who started benralizumab and received at least one injection at least 3 months before enrollment, either within the sampling program or as per routine clinical practice. 4. Patients who signed the informed consent and privacy form at enrollment visit. 5. Patients with available hospital medical chart since the start of benralizumab treatment within the sampling program or per clinical practice (index date).

Exclusion criteria

1. Patients who, during the observation period, received benralizumab in a clinical experimental trial. 2. Patients who, during the observation period, participated in studies imposing a specific patient's management strategy which does not correspond to the site's normal clinical practice.

Design outcomes

Primary

Measure	Time frame	Description
key features at benralizumab treatment start)	At baseline	Total IgE and eosinophils count in peripheral blood as measured at index date Lung function assessments Presence of comorbidities Previous severe exacerbations in the 12 months before index date. Previous treatments with biologics for asthma before index date. Maintenance asthma treatment(s) ongoing at index date.

Secondary

Measure	Time frame	Description
ICS and OCS change during benralizumab treatment	at 16 weeks	ICS dose change of any extent Change of OCS dose (final dose\* with respect to index date; if applicable)
IgE and eosinophils count during benralizumab treatment, and changes over time with respect to benralizumab treatment start	at 16 weeks	Descriptive statistics of total IgE and eosinophils count in peripheral blood as measured at the time points specified. Descriptive statistics of intra-patient changes over time in total IgE and eosinophils count in peripheral blood, at each time points specified with respect to index date (according to data availability).
lung function parameters during benralizumab treatment, and changes over time with respect to benralizumab treatment start	at 16 weeks	Descriptive statistics of lung function parameters as measured at the time points specified. Descriptive statistics of intra-patient changes over time in lung function parameters, at each time points specified with respect to index date (according to data availability).
patients' asthma control level and quality of life at benralizumab treatment start, during the observation period, and changes over time with respect to benralizumab treatment start	at 16 weeks	Descriptive statistics of Asthma Control Test (ACT) total score at index date (if available). Descriptive statistics of ACT total score at the time points specified in chapter 4.2 (according to data availability), along with proportion of patients with well-controlled asthma (i.e. ACT score major of 20). Descriptive statistics of intra-patient changes in ACT total score, at each time points specified in chapter 4.2 with respect to index date (according to data availability). Descriptive statistics of Asthma Quality of Life Questionnaire (AQLQ) total score at index date (if available). Descriptive statistics of AQLQ total score at the time points specified in chapter 4.2 (according to data availability). Descriptive statistics of intra-patient changes in AQLQ total score, at each time points specified in chapter 4.2 with respect to index date (according to data availability).
severe exacerbations during benralizumab treatment	at 16 weeks	Proportion of patients experiencing at least 1 severe exacerbation during benralizumab treatment. Severe exacerbation incidence rate during benralizumab treatment, calculated as the number of patients with at least one exacerbation occurred during benralizumab treatment (cases) divided by the person-time at risk considering the duration of observation while the patient was receiving benralizumab. Annual severe exacerbation rate, which will be calculated as the ratio between the total number of severe exacerbations occurred in the sample and the total number of person-years (i.e. the actual time-at-risk that all evaluable patients contributed to the study while they were in treatment with benralizumab).
healthcare resource utilization during benralizumab treatment	at 16 weeks	Descriptive statistics of total number (per patient) of the following healthcare resource utilization occurred during benralizumab treatment: GP/specialist visits for asthma, ER admissions for asthma, and hospitalizations for asthma.
benralizumab discontinuation	at 16 weeks	Proportion of patients with benralizumab permanent discontinuation during the observation period, and description of reasons.
biologic treatments during the observation period	at 16 weeks	Proportion of patients with subsequent biologic treatments for asthma, and description of type of treatment and reason for switch
patient's adherence to benralizumab treatment	at 16 weeks	Descriptive statistics of level of patient's adherence to benralizumab treatment, computed as the ratio (in percentage) between the number of actual injections received during the observation period over the number of expected injections (which will be estimated considering the injection schedulation specified in the SmPC).

Countries

Italy

Outcome results

None listed